Clean Science and Technology Ltd: Q1 FY27 Performance

Clean Science and Technology Ltd has reported record consolidated sales of ₹264 crore for the first quarter of FY27, marking a 7% increase sequentially. Standalone EBITDA stood at ₹87 crore with a 43% margin, and PAT was ₹73 crore with a 36% margin.

Reader Takeaway: Record sales and margin strength driven by product mix, but raw material costs pose a risk.

What just happened

Clean Science announced its Q1 FY27 financial results, showcasing record consolidated sales of ₹264 crore. The company's standalone performance featured EBITDA of ₹87 crore (43% margin) and PAT of ₹73 crore (36% margin). Key strategic developments include a 5-year exclusive supply contract with Kemin for BHA, BHT, TBHQ, and AP, and a partnership with Geneus Chem for advanced NOR HALS technology, potentially generating ₹300-350 crore over 3-4 years.

Why this matters

These results and strategic partnerships indicate strong growth potential and market penetration. The Kemin contract deepens an existing customer relationship, while the Geneus Chem deal aims to capture a significant share in the advanced NOR HALS market, currently dominated by global players. Investments in its subsidiary, Clean Fino Chem, further signal expansion plans.

The backstory

Clean Science has been focusing on expanding its product portfolio and geographical reach. The company has been investing in new capacities and technologies to enhance its offerings in specialty chemicals, particularly in areas like HALS (Hindered Amine Light Stabilizers), which contributed 22% of total sales in the quarter.

What changes now

The company expects to commercialize its Performance Chemical 2 capacity in Q3 FY27. The Hydroquinone and catechol plants are stabilizing for commercial supply. The new collaborations and contracts are expected to drive future revenue streams and solidify its market position.

Risks to watch

Management highlighted raw material price volatility, exacerbated by the Middle East crisis, as a primary challenge impacting costs. Geopolitical factors and potential supply chain disruptions remain a concern. Additionally, labor and gas-related challenges caused some production delays in Q1.

Peer comparison

While specific peer performance for Q1 FY27 is not detailed in the filing, Clean Science operates in the specialty chemicals sector, competing with both domestic and international players. Its focus on niche products like HALS and advanced intermediates positions it uniquely.

Context metrics (time-bound)

Consolidated sales for Q1 FY27 reached ₹264 crore, a 7% sequential growth. The Geneus Chem partnership has an estimated revenue potential of ₹300-350 crore over 3-4 years. The HALS business is projected to generate ₹250-300 crore in annualized revenue for FY27. Exports constitute about 50% of HALS sales.

What to track next

Investors will be keen to monitor the commercialization of new capacities, particularly Performance Chemical 2 in Q3 FY27. The realization of revenue from the Geneus Chem and Kemin collaborations, along with the management of raw material costs amidst geopolitical uncertainty, will be crucial.